Clinical Trial Update: Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of RX-0201 with everolimus in metastatic renal cell cancer has terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Cancer

Drugs mentioned

• Everolimus (everolimus)
• RX-0201 (null)

Snippet

Sponsor: Rexahn Pharmaceuticals, Inc. | Conditions: Metastatic Renal Cell Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-06-30